Net of expected cash to be acquired the deal is valued at roughly $4.6 billion. The acquisition is the largest in Vertex’s history, a spokeswoman for Vertex said.

Boston-based Vertex said late Wednesday it was acquiring Alpine for $65 a share in cash, or $4.9 billion, giving it access to the company’s product candidate for chronic kidney disease.

PORTLAND, Ore. (KOIN) — Just after 6:30 p.m. Thursday, a preliminary report of a 4.9 magnitude earthquake rattled parts of northern California. The USGS reported the quake happening just four ...

Vertex will acquire Alpine for $65 per share or around $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close ...

Tritax Big Box REIT plc's share price is currently trading about 5% higher than last year. The REIT's 2023 results showed relatively flat earnings despite increasing interest rates. The REIT's ...

opens new tab for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on Wednesday. The deal values each share of ...

Vertex Pharmaceuticals announced its biggest M&A play yet Wednesday evening, acquiring Alpine Immune Sciences for $4.9 billion. The deal was unanimously approved by the board of directors at both ...

Fixed asset investment grew 4.5 per cent against a year earlier in the quarter, boosted by a 9.9 per cent increase in manufacturing investment that was offset by a 9.5 per cent fall in property ...

New dwelling prices have risen by 4.9 per cent over the last 12 months as builders pass through higher costs for materials and labour. Economists say Wednesday's inflation numbers cement the view ...

Looking for an easy way to earn passive income? One Vanguard exchange-traded fund (ETF) pays a dividend yield of nearly 4.9%. ETFs offer a great way to invest in a large basket of stocks in one ...

The Alpine deal is worth $4.6 billion net of cash acquired, and is expected to close later this quarter, according to the statement. Vertex’s latest big deal came in 2019, when it agreed to buy ...

Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 billion, the companies announced Wednesday. It is the largest ...